Retreatment with rituximab offers a similar survival benefit as maintenance therapy in patients with low tumor burden follicular lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1542-4863|65|1|1-2

ISSN： 0007-9235

Source： CA: A CANCER JOURNAL FOR CLINICIANS, Vol.65, Iss.1, 2015-01, pp. : 1-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibody Therapy with Rituximab for Patients with Low-Grade Non-Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 22, Iss. 3, 1999-07 ,pp. : 184-190

Karger

Access to resources Recommend Favorite

The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 175, Iss. 1, 2016-10 ,pp. : 102-114

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low‐dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 277-278

John Wiley & Sons Inc

Access to resources Recommend Favorite

A retrospective study on the management of patients with rituximab refractory follicular lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 217-223

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 710-719

John Wiley & Sons Inc

Access to resources Recommend Favorite